Conv. Plasma
Nigella Sativa
Peg.. Lambda

All casirivimab/imdevimab..
Meta analysis
Home COVID-19 treatment researchCasirivimab/imdevimabCasirivimab/i.. (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Death/hospitalization 61% Improvement Relative Risk Hospitalization 61% Casirivimab/i..  Wei et al.  EARLY TREATMENT Is early treatment with casirivimab/imdevimab beneficial for COVID-19? Retrospective 19,564 patients in the USA (December 2020 - June 2021) Lower death/hosp. (p<0.0001) and hospitalization (p<0.0001) Wei et al., medRxiv, February 2022 Favors casirivimab/im.. Favors control

Real-world Effectiveness of Casirivimab and Imdevimab in Patients With COVID-19 in the Ambulatory Setting: An Analysis of Two Large US National Claims Databases

Wei et al., medRxiv, doi:10.1101/2022.02.28.22270796
Feb 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 4,396 casirivimab/imdevimab patients in the USA, showing lower combined mortality/hospitalization (CDM database) and lower hospitalization (PMTX+ database) with treatment.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron Liu, Sheward, Tatham, VanBlargan.
risk of death/hospitalization, 61.0% lower, HR 0.39, p < 0.001, treatment 23 of 1,116 (2.1%), control 27 of 5,291 (0.5%), Optum CDM, Cox proportional hazards.
risk of hospitalization, 61.0% lower, HR 0.39, p < 0.001, treatment 59 of 3,280 (1.8%), control 75 of 16,284 (0.5%), IQVIA PMTX+, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wei et al., 28 Feb 2022, retrospective, database analysis, USA, preprint, 8 authors, study period December 2020 - June 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Real-world Effectiveness of Casirivimab and Imdevimab in Patients With COVID-19 in the Ambulatory Setting: An Analysis of Two Large US National Claims Databases
PhD Wenhui Wei, Dana Murdock, Jessica J Jalbert, Vera Mastey, Robert J Sanchez, Boaz Hirshberg, David M Weinreich, PhD Mohamed Hussein
Background: In a phase III clinical trial, casirivimab and imdevimab (CAS+IMD) reduced the composite endpoint of COVID-19-related hospitalizations or all-cause mortality in outpatients at risk of severe disease. This study assessed real-world effectiveness of CAS+IMD. Methods: Data from Optum ® Clinformatics ® Data Mart (CDM) and IQVIA Pharmetrics Plus (PMTX+) were used to identify patients diagnosed with COVID-19 in ambulatory settings between December 2020 and March 2021 (PMTX+) and June 2021 (CDM), and either treated with CAS+IMD or untreated but treatment-eligible under Emergency Use Authorization. CAS+IMD-treated patients were matched to untreated patients and followed up to 30 days for the outcome of all-cause mortality or COVID-19-related hospitalizations (CDM) and COVID-19-related hospitalizations (PMTX+). Kaplan-Meier estimators were used to calculate outcome risks; Cox proportional-hazard models estimated adjusted hazard ratios (aHR) with 95% confidence intervals (CI). Results: For CDM, 1116 CAS+IMD-treated patients were matched to 5294 untreated patients; for PMTX+, 3280 CAS+IMD-treated patients were matched to 16,284 untreated patients. The 30-day outcome risk was 2.1% and 5.3% in treated and untreated cohorts, respectively (CDM), and the 30-day risk of COVID-19-related hospitalization was 1.9% and 4.8%, respectively (PMTX+); translating to a 61% lower adjusted outcome risk (CDM aHR 0.39 (95% CI 0.26-0.60; PMTX+ aHR 0.39 (95% CI 0.30-0.51). The benefit of treatment was maintained across multiple subgroups of highrisk patients; earlier intervention was associated with improved outcomes. . Conclusions: This real-world study further supports randomized clinical trial findings that treatment with CAS+IMD reduces the risk of hospitalization and mortality in patients infected with susceptible variants. .
A) Diagnosed with or tested positive for COVID-19 during the study period (n=566 755) Received CAS+IMD during the study period (n=1588)
Anderson, Smith, Edupuganti, Yan, Masi et al., Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019, Open Forum Infect Dis
Bierle, Ganesh, Tulledge-Scheitel, Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities, J Infect Dis
Cavazzoni, Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant
Charlson, Pompei, Ales, Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis
Chilimuri, Mantri, Gurjar, Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience, J Natl Med Assoc
Close, Jones, Jentoft, Mcauley, Outcome Comparison of High-Risk Native American Patients Who Did or Did Not Receive Monoclonal Antibody Treatment for COVID-19, JAMA Netw Open
Cooper, Christensen, Salazar, Real-world Assessment of 2,879 COVID-19 Patients Treated with Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study, Open Forum Infect Dis
Falcone, Tiseo, Valoriani, Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern, Infect Dis Ther
Ganesh, Philpot, Bierle, Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019, J Infect Dis
Hall, Wellner, Confidence bands for a survival curve from censored data, Biometrika
Kakinoki, Yamada, Tanino, Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients, Open Forum Infect Dis
Kaplan, Meier, Nonparametric estimation from incomplete observations, J Am Stat Assoc
Linden, Samuels, Using balance statistics to determine the optimal number of controls in matching studies, J Eval Clin Pract
Mccreary, Bariola, Wadas, Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19, medRxiv, doi:10.1101/2021.11.30.21266756
Planas, Saunders, Maes, Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization, bioRxiv
Razonable, Aloia, Anderson, A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model, Mayo Clin Proc
Razonable, Pawlowski, Horo, Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19, EClinicalMedicine
Verderese, Stepanova, Lam, Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience, Clin Infect Dis, doi:10.1093/cid/ciab579
Webb, Buckel, Vento, Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19, Open Forum Infect Dis
Weinreich, Sivapalasingam, Norton, REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19, N Engl J Med
Wilhelm, Widera, Grikscheit, Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies, medRxiv,
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop